TATE and KN046 in MCRC
Launched by ZHEJIANG RAYGENE PHARMACEUTICALS CO., LTD · Feb 13, 2025
Trial Information
Current as of May 30, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Liver metastatic MSS/pMMR-mCRC;
- • mCRC progressed on at least two lines of standard chemotherapy;
- • Measurable disease;
- • ECOG 0-1;
- • Adequate organ function
- Exclusion Criteria:
- • Prior organ transplantation;
- • Oxygen saturation less than 92% in room air;
- • Prior autoimmune disorder;
- • Major GI bleeding in the last 2 months;
- • Prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody therapy, or any other antibody or drug that specifically targets T-cell co-stimulation or immune checkpoint pathways.
About Zhejiang Raygene Pharmaceuticals Co., Ltd
Zhejiang Raygene Pharmaceuticals Co., Ltd. is a leading biopharmaceutical company based in China, dedicated to advancing innovative therapies in the fields of oncology and autoimmune diseases. With a robust pipeline of cutting-edge drug candidates, Raygene focuses on the development of precision medicine solutions that leverage advanced biotechnology and genomics. Committed to rigorous clinical research and development, the company aims to improve patient outcomes through its high-quality, evidence-based therapeutic products. Raygene's expertise in drug discovery and development is complemented by strategic collaborations with academic institutions and industry partners, positioning it as a key player in the global biopharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported